Treatment of adult atopic dermatitis with low-dose (3 mg/kg per day) cyclosporine

R. Caputo, S. Veraldi

Research output: Contribution to journalArticle

Abstract

A group of 18 adult patients, with chronic, severe and therapy-resistant atopic dermatitis, were treated with 3 mg/kg per day cyclosporine for 1-8 months (mean 5.3 months). All patients were treated in the period from September-October to April-May. During the summer months only exposure to sunlight was recommended. In 15 patients improvement in clinical signs and pruritus, and a beneficial impact on the quality of life were observed. Side-effects occurred in 6 patients, but they did not lead to suspension of therapy. No changes in blood pressure were observed. No renal or hepatic side-effects were recorded. During follow-up (ranging from 17 to 42 months, with a mean of 23.8 months), 11 patients were in good health and the dermatitis was controlled with topical nonsteroidal products and exposure to sunlight. Four patients developed a relapse for which therapy with cyclosporine was again started. Cyclosporine can be successfully used in the treatment of adult patients with chronic, severe and therapy-resistant atopic dermatitis and it appears to be effective even at a dose of 3 mg/kg per day. Low-dose long-term treatment can lead in some patients to complete remission of the disease. The proposed therapeutic regimen (treatment from September-October to April-May and only exposure to sunlight during the summer months) is innovative and is particularly suited to the Mediterranean and similar climates.

Original languageEnglish
Pages (from-to)3-6
Number of pages4
JournalJournal of Dermatological Treatment
Volume7
Issue number1
Publication statusPublished - Mar 1996

Fingerprint

Atopic Dermatitis
Cyclosporine
Sunlight
Therapeutics
Dermatitis
Pruritus
Climate
Suspensions
Quality of Life
Blood Pressure
Kidney
Recurrence
Liver
Health

Keywords

  • Atopic dermatitis
  • Cyclosporine

ASJC Scopus subject areas

  • Dermatology

Cite this

Treatment of adult atopic dermatitis with low-dose (3 mg/kg per day) cyclosporine. / Caputo, R.; Veraldi, S.

In: Journal of Dermatological Treatment, Vol. 7, No. 1, 03.1996, p. 3-6.

Research output: Contribution to journalArticle

@article{4cdb4ad16cd34774b44957faf652e050,
title = "Treatment of adult atopic dermatitis with low-dose (3 mg/kg per day) cyclosporine",
abstract = "A group of 18 adult patients, with chronic, severe and therapy-resistant atopic dermatitis, were treated with 3 mg/kg per day cyclosporine for 1-8 months (mean 5.3 months). All patients were treated in the period from September-October to April-May. During the summer months only exposure to sunlight was recommended. In 15 patients improvement in clinical signs and pruritus, and a beneficial impact on the quality of life were observed. Side-effects occurred in 6 patients, but they did not lead to suspension of therapy. No changes in blood pressure were observed. No renal or hepatic side-effects were recorded. During follow-up (ranging from 17 to 42 months, with a mean of 23.8 months), 11 patients were in good health and the dermatitis was controlled with topical nonsteroidal products and exposure to sunlight. Four patients developed a relapse for which therapy with cyclosporine was again started. Cyclosporine can be successfully used in the treatment of adult patients with chronic, severe and therapy-resistant atopic dermatitis and it appears to be effective even at a dose of 3 mg/kg per day. Low-dose long-term treatment can lead in some patients to complete remission of the disease. The proposed therapeutic regimen (treatment from September-October to April-May and only exposure to sunlight during the summer months) is innovative and is particularly suited to the Mediterranean and similar climates.",
keywords = "Atopic dermatitis, Cyclosporine",
author = "R. Caputo and S. Veraldi",
year = "1996",
month = "3",
language = "English",
volume = "7",
pages = "3--6",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Treatment of adult atopic dermatitis with low-dose (3 mg/kg per day) cyclosporine

AU - Caputo, R.

AU - Veraldi, S.

PY - 1996/3

Y1 - 1996/3

N2 - A group of 18 adult patients, with chronic, severe and therapy-resistant atopic dermatitis, were treated with 3 mg/kg per day cyclosporine for 1-8 months (mean 5.3 months). All patients were treated in the period from September-October to April-May. During the summer months only exposure to sunlight was recommended. In 15 patients improvement in clinical signs and pruritus, and a beneficial impact on the quality of life were observed. Side-effects occurred in 6 patients, but they did not lead to suspension of therapy. No changes in blood pressure were observed. No renal or hepatic side-effects were recorded. During follow-up (ranging from 17 to 42 months, with a mean of 23.8 months), 11 patients were in good health and the dermatitis was controlled with topical nonsteroidal products and exposure to sunlight. Four patients developed a relapse for which therapy with cyclosporine was again started. Cyclosporine can be successfully used in the treatment of adult patients with chronic, severe and therapy-resistant atopic dermatitis and it appears to be effective even at a dose of 3 mg/kg per day. Low-dose long-term treatment can lead in some patients to complete remission of the disease. The proposed therapeutic regimen (treatment from September-October to April-May and only exposure to sunlight during the summer months) is innovative and is particularly suited to the Mediterranean and similar climates.

AB - A group of 18 adult patients, with chronic, severe and therapy-resistant atopic dermatitis, were treated with 3 mg/kg per day cyclosporine for 1-8 months (mean 5.3 months). All patients were treated in the period from September-October to April-May. During the summer months only exposure to sunlight was recommended. In 15 patients improvement in clinical signs and pruritus, and a beneficial impact on the quality of life were observed. Side-effects occurred in 6 patients, but they did not lead to suspension of therapy. No changes in blood pressure were observed. No renal or hepatic side-effects were recorded. During follow-up (ranging from 17 to 42 months, with a mean of 23.8 months), 11 patients were in good health and the dermatitis was controlled with topical nonsteroidal products and exposure to sunlight. Four patients developed a relapse for which therapy with cyclosporine was again started. Cyclosporine can be successfully used in the treatment of adult patients with chronic, severe and therapy-resistant atopic dermatitis and it appears to be effective even at a dose of 3 mg/kg per day. Low-dose long-term treatment can lead in some patients to complete remission of the disease. The proposed therapeutic regimen (treatment from September-October to April-May and only exposure to sunlight during the summer months) is innovative and is particularly suited to the Mediterranean and similar climates.

KW - Atopic dermatitis

KW - Cyclosporine

UR - http://www.scopus.com/inward/record.url?scp=0029863683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029863683&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029863683

VL - 7

SP - 3

EP - 6

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 1

ER -